Win the Patent Fight: Hatch-Waxman Litigation Strategies for Brand and Generic Manufacturers
The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been […]
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets
Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos
Why Branded Generics Dominate the Pharmaceutical Landscape in Emerging Markets Read Post »
Bundle or Lose: The Biopharma Data Provider’s Guide to Selling Patent, Clinical, and Litigation Intelligence Together
The companies winning enterprise contracts in biopharma data intelligence aren’t selling better patent databases. They’re selling a connected answer to
The patent cliff is not a crisis for equipment suppliers. It’s a sales calendar: Sell Continuous Manufacturing Before the Drug Patent Cliff Hits
Every major drug patent expiration triggers a predictable downstream event: the originator company races to defend margin, and a dozen
Oncology’s Patent Cliff Is Your Sales Pipeline: A Business Development Guide for High-Containment Equipment Suppliers Targeting Oncology Loss-of-Exclusivity Opportunities
The LOE Wave Nobody in Equipment Sales Is Talking About Between 2024 and 2029, roughly $130 billion worth of branded
The Biopharma Vendor’s Guide to Winning Contracts Using Drug Patent Loss of Exclusivity Data
The Revenue Cliff Is Real, and So Is Your Window Every year, billions of dollars in branded pharmaceutical revenue evaporate
Track Global Drug Patent Expiry by Geography — Without Hiring a Team of Analysts
The Geography Problem Nobody Warns You About The patent expired. You know the date, you have it in your spreadsheet,
Track Global Drug Patent Expiry by Geography — Without Hiring a Team of Analysts Read Post »
Read the Patent Cliff Before Everyone Else Does: How to Evaluate Biosimilar First-Mover Advantage
The race for biosimilar first-mover advantage is decided long before the FDA approves a single molecule. It is decided in
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs
The Question That Drives a $200 Billion Market Every time a pharmacist hands a patient a generic substitute for a
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
